BlueRock Therapeutics said it developed an automated system for high-throughput auditing in cell therapy workflows, built to handle cell culture, liquid handling, and small-volume sample processing. The company described the system as addressing a gap between widely available automation platforms for small molecules and the lower-volume realities of cell therapy analytics. BlueRock said its customized approach is designed in collaboration with Hamilton Robotics and aims to reduce the cost and turnaround time of analytical audits as the field moves toward higher-volume, commercial-scale manufacturing. The announcement frames the system as adaptable beyond BlueRock’s internal programs, targeting an industry need for scalable analytics without requiring larger sample sizes that can drive assay cost and operational burden.